Ireland -
English -
HPRA (Health Products Regulatory Authority)
acarbose tecnimede 50 milligram tablets
multigeneris gmbh - acarbose - tablets - 50 milligram
Ireland -
English -
HPRA (Health Products Regulatory Authority)
acarbose tecnimede
multigeneris gmbh - acarbose - tablets - 50 milligram
Ireland -
English -
HPRA (Health Products Regulatory Authority)
acarbose tecnimede
multigeneris gmbh - acarbose - tablets - 100 milligram
Ireland -
English -
HPRA (Health Products Regulatory Authority)
acarbose tecnimede 100 milligram tablets
multigeneris gmbh - acarbose - tablets - 100 milligram
European Union -
English -
EMA (European Medicines Agency)
litak
lipomed gmbh - cladribine - leukemia, hairy cell - antineoplastic agents - litak is indicated for the treatment of hairy-cell leukaemia.
Singapore -
English -
HSA (Health Sciences Authority)
synagis sterile powder for injection 100 mgvial
abbvie pte. ltd. - palivizumab - injection, powder, for solution - 100 mg/vial (100mg/ml) - palivizumab 100 mg/vial (100mg/ml)
Armenia -
English -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
captopril denk 25 tablets
denk pharma gmbh & co. kg - captopril - tablets - 25mg
Armenia -
English -
Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
captopril denk 25
denk pharma gmbh & co. kg - captopril - tablets - 25mg
United Kingdom -
English -
MHRA (Medicines & Healthcare Products Regulatory Agency)
litak 10mg5ml solution for injection vials
lipomed gmbh - cladribine - solution for injection - 2mg/1ml
European Union -
English -
EMA (European Medicines Agency)
respreeza
csl behring gmbh - alpha1-proteinase inhibitor (human) - genetic diseases, inborn, lung diseases - antihemorrhagics, - respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes pizz, piz(null), pi(null,null), pisz). patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (fev1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.,